Mutations in the KEAP1 or NFE2L2 genes are mutually exclusive and occur in NSCLC patients with a variable incidence (3.5–15% for KEAP1; 12–17% for NFE2L2), with the first ones mainly clustered with the lung adenocarcinoma (LUAD) histology [11,12,13]. Here, NFE2L2 is linked to non-small cell lung carcinoma.